Consumer medicine information

APX-Gliclazide

Gliclazide

BRAND INFORMATION

Brand name

APX-Gliclazide

Active ingredient

Gliclazide

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using APX-Gliclazide.

SUMMARY CMI

APX-GLICLAZIDE Tablets

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using APX-GLICLAZIDE?

APX-GLICLAZIDE contains the active ingredient gliclazide. APX-GLICLAZIDE is used to control blood glucose in people with Type 2 diabetes mellitus when diet and exercise are not enough to control your blood glucose.

For more information, see Section 1. Why am I using APX-GLICLAZIDE? in the full CMI.

2. What should I know before I use APX-GLICLAZIDE?

Do not use if you have ever had an allergic reaction to gliclazide, or other sulphonylurea, sulfonamide (sulfur) antibiotics, certain types of fluid tablets (thiazide diuretics), or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use APX-GLICLAZIDE? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with APX-GLICLAZIDE and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use APX-GLICLAZIDE?

Swallow the tablets with a glass of water at about the same time each day, usually with breakfast.

More instructions can be found in Section 4. How do I use APX-GLICLAZIDE? in the full CMI.

5. What should I know while using APX-GLICLAZIDE?

Things you should do
  • Tell any doctors, dentists and pharmacists who are treating you that you are taking APX-GLICLAZIDE.
  • Check your blood glucose levels regularly to know if your diabetes is being controlled properly.
Things you should not do
  • Do not stop taking it or change the dose without checking with your doctor.
  • Do not give this medicine to anyone else, even if their symptoms are similar to yours.
  • Do not skip meals while taking APX-GLICLAZIDE.
Driving or using machines
  • APX-GLICLAZIDE may cause dizziness in some people. Drinking alcohol can make this worse. If either of these occur, do not drive, operate machinery or do anything else that could be dangerous.
Drinking alcohol
  • If you drink alcohol while taking APX-GLICLAZIDE, you may get flushing, headache, breathing difficulties, rapid heart beat, stomach pains or feel sick and vomit.
Looking after your medicine
  • Keep APX-GLICLAZIDE Tablets in a cool dry place where the temperature is below 30°C.

For more information, see Section 5. What should I know while using APX-GLICLAZIDE? in the full CMI.

6. Are there any side effects?

There are a number of side effects associated with this medicine. It is important to be aware of them so that you can identify any symptoms if they occur (see the full CMI for more details). The serious side effects are: Skin rash, redness itching and/or hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty), and rash progressing to widespread blistering or peeling of the skin and may be the first sign of rare life-threatening conditions. The common side effects are Hypoglycaemia, hyperglycaemia (for more information, see section on recognising and treating hypoglycaemia and hyperglycaemia), runny or blocked nose, sneezing, facial pressure or pain, bronchitis, sore throat and discomfort when swallowing, upper respiratory infection, coughing, back pain, arthralgia, arthrosis, high blood pressure, chest pain, headache, unusual weakness, viral infection, urinary tract infection, dizziness, stomach upset with symptoms like feeling sick, stomach pain, vomiting, diarrhoea, or constipation.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

APX-GLICLAZIDE Tablets

Active ingredient: gliclazide


Consumer Medicine Information (CMI)

This leaflet provides important information about using APX-GLICLAZIDE tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking APX-GLICLAZIDE against the benefits this medicine is expected to have for you.

Talk to your doctor, pharmacist or diabetes educator if you have any concerns about taking this medicine.

Keep this leaflet with your medicine. You may need to read it again.

Where to find information in this leaflet:

1. Why am I using APX-GLICLAZIDE?
2. What should I know before I use APX-GLICLAZIDE?
3. What if I am taking other medicines?
4. How do I use APX-GLICLAZIDE?
5. What should I know while using APX-GLICLAZIDE?
6. Are there any side effects?
7. Product details

1. Why am I using APX-GLICLAZIDE?

APX-GLICLAZIDE is used to control blood glucose in people with Type 2 diabetes mellitus. This type of diabetes is also called non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes.

APX-GLICLAZIDE is used when diet and exercise are not enough to control your blood glucose levels. It can be used alone, or in combination with other medicines for treating diabetes.

APX-GLICLAZIDE is available only with a doctor's prescription.

How it works:

APX-GLICLAZIDE belongs to a group of medicines called sulphonylureas. These medicines lower blood glucose by increasing the amount of insulin produced by your pancreas.

If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose).

Hypoglycaemia

Hypoglycaemia (low blood glucose) can occur suddenly. Signs may include:

  • weakness, trembling or shaking
  • sweating
  • lightheadedness, dizziness, headache or lack of concentration
  • irritability, tearfulness or crying
  • hunger
  • numbness around the lips and tongue.

If not treated promptly, these may progress to:

  • loss of co-ordination
  • slurred speech
  • confusion
  • fits or loss of consciousness

Hyperglycaemia

Hyperglycaemia (high blood glucose) usually occurs more slowly than hypoglycaemia. Signs of hyperglycaemia may include:

  • lethargy or tiredness
  • headache
  • thirst
  • passing large amounts or urine
  • blurred vision

Long-term hyperglycaemia can lead to serious health problems such as heart disease, blindness, poor blood circulation, gangrene, and kidney damage.

2. What should I know before I use APX-GLICLAZIDE?

Warnings

Do not use APX-GLICLAZIDE if:

  • you are allergic to:
    - medicines containing gliclazide or any other sulphonylurea
    - sulfonamide (sulfur) antibiotics
    - certain types of fluid tablets (thiazide diuretics)
    - any of the ingredients listed at the end of this leaflet.
  • you have any of the following medical conditions:
    - type 1 diabetes mellitus that is well controlled by insulin alone
    - unstable diabetes that is not well controlled
    - diabetic acidosis
    - diabetic coma
    - severe kidney disease
    - you are taking an antibiotic medicine containing the active ingredient miconazole
    - severe liver disease.
  • you are pregnant or plan to become pregnant.
  • you are breastfeeding or plan to breastfeed.
  • the expiry date (Exp.) printed on the pack has passed.
  • the packaging shows signs of tampering or the tablets do not look quite right.

If you are not sure whether you should be taking APX-GLICLAZIDE, talk to your doctor.

Check with your doctor or pharmacist if you:

  • have allergies to any other medicines, foods, preservatives or dyes.
  • have or have had any of the following medical conditions:
    - liver problems
    - kidney problems
    - a history of diabetic coma
    - heart failure
    - adrenal, pituitary or thyroid problems.
  • have a family history of or know you have the hereditary condition glucose-6-phosphate dehydrogenase (G6PD) deficiency (abnormality of red blood cells), lowering of the haemoglobin level and breakdown of red blood cells (haemolytic anaemia) can occur.
  • have any medical condition, or do anything, that may increase the risk of hyperglycaemia - for example:
    - you are ill or feeling unwell (especially with fever or infection).
    - you are injured.
    - you are having surgery.
    - you are taking less exercise than normal.
    - you are eating more carbohydrate than normal.
    - drinking alcoholic drinks.
    - not eating regular meals.
    - taking more exercise than usual.
  • take any medicines for any other condition.

Alcohol, diet, exercise and your general health all strongly affect the control of your diabetes.

Discuss these with your doctor.

If you have not told your doctor or pharmacist about any of the above, tell them before you start taking or are given APX-GLICLAZIDE.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant.

This medicine may affect your developing baby if you take it during pregnancy. Your doctor can discuss with you the risks and benefits involved.

Insulin is more suitable for controlling blood glucose during pregnancy. Your doctor will usually replace APX-GLICLAZIDE with insulin while you are pregnant.

Tell your doctor if you are breastfeeding or plan to breastfeed.

APX-GLICLAZIDE passes into breast milk and your baby may be harmed.

If you have not told your doctor about any of the above, tell him/her before you start taking APX-GLICLAZIDE.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may be affected by APX-GLICLAZIDE or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor will advise you.

Some medicines may lead to low blood glucose (hypoglycaemia) by increasing the blood glucose lowering effect of APX-GLICLAZIDE. These include:

  • some medicines used to treat fungal or yeast infections (miconazole which is contraindicated)
  • alcohol
  • other medicines used to treat diabetes (such as biguanides and insulin)
  • some medicines used to treat high blood pressure and other heart conditions (including angiotensin receptor blocker, beta-blockers)
  • some medicines used to treat depression and other mental illness (MAOIs)
  • some cholesterol-lowering
  • medicines (clofibrate)
  • some medicines used to treat arthritis, pain and inflammation (including high dose aspirin, ibuprofen, phenylbutazone)
  • some antibiotics (chloramphenicol; tetracyclines; long-acting sulphonamides)
  • some medicines used to treat acid reflux and stomach ulcers

Some medicines may lead to high blood glucose (hyperglycaemia) by weakening the blood glucose lowering effect of APX-GLICLAZIDE. These include:

  • alcohol
  • some medicines for epilepsy (danazol)
  • some medicines used to treat depression and other mental illness (chlorpromazine)
  • some hormones used in hormone replacement therapy and oral contraceptives (oestrogen, progesterone)
  • St John's Wort (Hypericum perforatum) preparations used to treat depression
  • some medicines for asthma (salbutamol, intravenous terbutaline).
  • barbiturates, medicines used for sedation
  • glucocorticoids

Some medicines may lead to unstable blood glucose (low blood sugar and high blood sugar) when taken at the same time as APX-GLICLAZIDE, especially in elderly patients. These include:

  • A class of antibiotics called fluoroquinolones.

APX-GLICLAZIDE may change the effects of some other medicines. These include:

  • some medicines used to prevent blood clots (warfarin)

You may need different amounts of your medicine or you may need to take different medicines. Your doctor, pharmacist or diabetes educator can tell you what to do if you are taking any of these medicines. They also have a more complete list of medicines to be careful with or avoid while taking APX-GLICLAZIDE.

Ask your doctor or pharmacist if you are not sure if you are taking any of these medicines.

4. How do I use APX-GLICLAZIDE?

How much to take

Take Gliclazide tablets exactly as your doctor has prescribed.

Follow all directions given to you by your doctor or pharmacist. They may differ from the information contained in this leaflet.

If you do not understand the instructions on the box ask your doctor or pharmacist for help.

Your doctor will tell you how many tablets to take each day. They may increase or decrease the dose, depending on your blood glucose levels.

When to take / use APX-GLICLAZIDE

Swallow the tablets with a glass of water.

APX-GLICLAZIDE tablets can be broken in half. However, they should not be crushed or chewed. Crushing or chewing the tablets may change the effectiveness of the tablet.

It is important to take your APX-GLICLAZIDE at the same time each day - usually with breakfast. Taking APX-GLICLAZIDE with food can help to minimise the risk of hypoglycaemia.

Do not skip meals while taking APX-GLICLAZIDE.

If you forget to use APX-GLICLAZIDE

APX-GLICLAZIDE should be used regularly at the same time each day, usually with breakfast. If you miss your dose at the usual time, take another as soon as possible. Then go on as before.

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise, take it as you remember (with food), then go back to taking your tablets as you would normally.

Missed doses can cause high blood glucose (hyperglycaemia).

If you are not sure whether to skip the dose, talk to your doctor or pharmacist.

Do not take a double dose to make up for the dose you missed.

If you double a dose, this may cause low blood glucose (hypoglycaemia).

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you use too much APX-GLICLAZIDE

If you think that you have used too much APX-GLICLAZIDE, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

If you take too much APX-GLICLAZIDE together with other medicines for diabetes or alcohol, you may experience symptoms of low blood glucose (hypoglycaemia).

If not treated quickly, these symptoms may progress to loss of co-ordination, slurred speech, confusion, loss of consciousness and fitting.

At the first signs of hypoglycaemia, raise your blood glucose quickly by following the instructions at “Recognising and treating hyPOglycaemia”, Section 5. What should I know while using APX-GLICLAZIDE?

If you experience any of these symptoms, immediately get medical help.

5. What should I know while using APX-GLICLAZIDE?

Things you should do

If you become pregnant while you are taking APX-GLICLAZIDE, tell your doctor.

Tell all doctors, dentists, pharmacists and diabetes educators who are involved with your treatment that you are taking APX-GLICLAZIDE.

If you are about to start any new medicine, tell your doctor or pharmacist that you are taking APX-GLICLAZIDE.

Take APX-GLICLAZIDE exactly as your doctor has prescribed. Otherwise you may not get the full benefits from treatment.

Continue taking APX-GLICLAZIDE for as long as your doctor recommends. Make sure you keep enough APX-GLICLAZIDE to last over weekends and holidays. APX-GLICLAZIDE will help control your diabetes but will not (cure) it. Therefore, you may have to take it for a long time.

Make sure you check your blood glucose levels regularly. This is the best way to tell if your diabetes is being controlled properly. Your doctor or diabetes educator will show you how and when to do this.

Make sure that you, your friends, family, and work colleagues can recognise the symptoms of hypoglycaemia and hyperglycaemia and know how to treat them.
Instructions for recognising and treating hypoglycaemia and hyperglycaemia in this this section can help you with this.

Visit your doctor regularly so that they can check on your progress. Carefully follow your doctor's and dietician's advice on diet, drinking alcohol and exercise.

Tell your doctor immediately if you notice the return of any symptoms of hyperglycaemia that you had before starting APX-GLICLAZIDE.

These may include lethargy or tiredness, headache, thirst, passing large amounts of urine and blurred vision. These may be signs that APX-GLICLAZIDE is no longer working, even though you may have been taking it successfully for some time.

Protect your skin when you are in the sun, especially between 10am and 3pm.

Sulphonylureas (the group of medicines that Gliclazide Lupin MR belongs to) may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight may cause a skin rash, itching, redness, or a severe sunburn.

If outdoors, wear protective clothing and use a 30+ sunscreen. Also, be especially careful not to let your blood glucose levels fall too low.

If you are travelling, it is a good idea to:

  • wear some form of identification showing you have diabetes.
  • carry some form of sugar to treat hypoglycaemia if it occurs, for example, sugar sachets or jelly beans.
  • carry emergency food rations in case of a delay, for example, dried fruit, biscuits or muesli bars.
  • keep Gliclazide Lupin MR readily available.

If you become sick with a cold, fever or flu, it is very important to continue taking Gliclazide Lupin MR, even if you feel unable to eat your normal meal. If you have trouble eating solid food, use sugar-sweetened drinks as a carbohydrate substitute or eat small amounts of bland food.

Your diabetes educator or dietician can give you a list of foods to use for sick days.

Call your doctor straight away if you:

  • notice the return of any symptoms of APX-GLICLAZIDE. These may include lethargy or tiredness, headache, thirst, passing large amounts of urine and blurred vision. These may be signs that APX-GLICLAZIDE is no longer working, even though you.
  • are pregnant or planning to become pregnant, or are breastfeeding.
  • notice your skin does appear to be burning despite wearing protective clothing and using a 30+ sunscreen outdoors.
  • Develop/get any new medical condition, or do anything unusual, that may increase the risk of hyperglycaemia-for example:
    - you are ill or feeling unwell (especially with fever or infection);
    - you are injured;
    - you are having surgery;
    - taking less Gliclazide Lupin MR than prescribed;
    - you are taking less exercise than normal;
    - you are eating more carbohydrate than normal;
    - drinking alcoholic drinks;
    - not eating regular meals;
    - taking more exercise than usual.

Remind any doctor, dentist, pharmacist, or diabetes educators you visit that you are APX-GLICLAZIDE

Things you should not do

  • Do not stop using this medicine or change the dosage, without checking with your doctor.
  • Do not give APX-GLICLAZIDE to anyone else, even if they have the same condition as you.
  • Do not use APX-GLICLAZIDE to treat other complaints unless your doctor tells you to.
  • Do not skip meals while taking APX-GLICLAZIDE

Recognising and treating hyPOglycaemia (very LOW blood sugar levels)

Hypoglycaemia may occur during APX-GLICLAZIDE treatment.

The first signs of hypoglycaemia are usually weakness, trembling or shaking, sweating, lightheadedness, dizziness, headache or lack of concentration, irritability, tearfulness,hunger, and/ or numbness around the lips and tongue.

At the first signs of hypoglycaemia take some sugar to raise your blood sugar level quickly.

Do this by eating 5 to 7 jelly beans, 3 teaspoons of sugar or honey, drinking half a can of non-diet soft drink, taking 2-3 glucose tablets or a tube of glucose gel.

Then take some extra carbohydrates

such as plain biscuits, fruit or milk - unless you are within 10-15 minutes of your next meal. Taking this extra carbohydrate will help to prevent a second drop in your blood glucose level.

If not treated quickly, hypoglycaemia symptoms may progress to loss of co-ordination, slurred speech, confusion, fits or loss of consciousness.

If hypoglycaemia symptoms do not get better straight away after taking sugar then go to the Accident and Emergency department at your nearest hospital - if necessary by calling an ambulance.

Contact your doctor or diabetes educator for advice if you are concerned about hypoglycaemia.

Recognising and treating hyPERglycaemia (HIGH blood sugar levels)

Some people may feel fine when their glucose levels are high. Others notice symptoms of hyperglycaemia like tiredness, lack of energy, thirst, passing large amounts of urine, headache, and/or blurred vision.

If you notice symptoms of hyperglycaemia, or your blood sugar levels are high, tell your doctor immediately. You may need adjustments of the dose or type of medicines you are taking.

It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health Problems, which can involve the heart, eyes, circulation, and/or kidneys.

If you experience any of the signs of hyperglycaemia (high blood glucose) contact your doctor or diabetes educator for advice immediately

Driving or using machines

Be careful driving or operating machinery until you know how APX-GLICLAZIDE affects you.

Also, be especially careful not to let your blood glucose levels fall too low.

Gliclazide may cause dizziness or drowsiness in some people. Low blood glucose levels may also slow your reaction time and affect your ability to drive or operate machinery.

If this occurs, do not drive, operate machinery or do things that could be dangerous if you are not alert.

A section at the end of this leaflet contains advice about recognising and treating hypoglycaemia.

Drinking alcohol can make this worse. If either of these occurs, do not drive, operate machinery or do anything else that could be dangerous.

Drinking alcohol

Tell your doctor if you drink alcohol.

If you drink alcohol while taking APX-GLICLAZIDE, you may get flushing, headache, breathing difficulties, rapid heart beat, stomach pains or feel sick and vomit.

Looking after your medicine

  • Keep APX-GLICLAZIDE tablets in the original pack until it is time to take them.
  • Keep APX-GLICLAZIDE tablets in a cool dry place where the temperature is below 30°C.

Do not store APX-GLICLAZIDE, or any other medicine, in the bathroom or near a sink.

Do not leave medicines in the car or on window sills. Heat and dampness can destroy some medicines.

Keep your medicines where children cannot reach them. A locked cupboard at least one-and-a-half metres (1.5 m) above the ground is a good place to store medicines.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Less serious side effects

Less serious side effectsWhat to do
  • HyPOglycaemia and hyPERglycaemia. Section 5 of this leaflet contains advice about recognising and treating hyPOglycaemia and hyPERglycaemia.
  • Runny or blocked nose, sneezing, facial pressure or pain, bronchitis, sore throat and discomfort when swallowing, upper respiratory infection, coughing.
  • Back pain, arthralgia, arthrosis.
  • High blood pressure, chest pain.
  • Headache, unusual weakness.
  • Viral infection, urinary tract infection.
  • Dizziness.
  • Stomach upset with symptoms like feeling sick, stomach pain, vomiting, diarrhoea, or constipation.
  • Decrease in the number of cells in the blood (eg. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. These symptoms usually vanish when the treatment is discontinued.
  • Increase of some hepatic enzyme levels, and exceptionally a liver disease.
  • Your vision may be affected for a short time especially at the start of treatment. This effect is due to changes in blood sugar levels.
Speak to your doctor or pharmacist if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
  • Skin rash, redness itching and/or hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue, or throat that may result in breathing difficulty) have been reported. Rash may progress to widespread blistering or peeling of the skin and may be the first sign of rare life-threatening conditions (eg. Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and severe hypersensitivity reactions (DRESS)). Exceptionally, DRESS have been reported initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.
  • As for other sulphonylureas, the following adverse events have been observed: cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (eg. jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.
Stop taking APX-GLICLAZIDE and call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is available with a doctor's prescription.

What APX-GLICLAZIDE contains

Active ingredient
(main ingredient)
gliclazide
Other ingredients
(inactive ingredients)

APX-GLICLAZIDE tablets contain:

  • lactose monohydrate
  • microcrystalline cellulose
  • povidone
  • sodium starch glycollate type A
  • purified talc
  • magnesium stearate.
Potential allergensThe tablets contain sugars as lactose.

APX-GLICLAZIDE does not contain gluten, sucrose, tartrazine or any other azo dyes.

Do not take this medicine if you are allergic to any of these ingredients.

What APX-GLICLAZIDE looks like

APX-GLICLAZIDE is a white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other. AUST R 337479

The tablets are available in blister pack of 100's.

Who distributes APX-GLICLAZIDE

Arrotex Pharmaceuticals Pty Ltd
15-17 Chapel St
Cremorne VIC 3121
www.arrotex.com.au

This leaflet was prepared in January 2025

Published by MIMS March 2025

BRAND INFORMATION

Brand name

APX-Gliclazide

Active ingredient

Gliclazide

Schedule

S4

 

1 Name of Medicine

Gliclazide.

2 Qualitative and Quantitative Composition

APX-Gliclazide tablets contain 80 mg of gliclazide.

Excipients with known effect.

Contains sugars as lactose.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Uncoated tablets.
A white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other.

4 Clinical Particulars

4.1 Therapeutic Indications

Diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.

4.2 Dose and Method of Administration

For adult use only.
The dosage of gliclazide should be carefully titrated to maintain optimal control at the various possible dose levels. Dosage should be initiated at 40 mg (½ tablet) daily and may be increased if necessary up to 320 mg (four tablets) daily. Doses up to 160 mg daily may be taken in a single dose but preferably at the same time each morning. Doses in excess of 160 mg should be taken in divided doses in the morning and evening.
In general, the dosage will depend on the severity of the glycaemia with ongoing adjustments made in order to obtain the optimal response at the lowest dosage.
Treatment with gliclazide does not obviate the necessity of maintaining standard dietary regulations.

4.3 Contraindications

Gliclazide should not be used in diabetes complicated by acidosis, ketosis or coma, or in patients with a history of repeated episodes of ketoacidosis or coma.
Juvenile onset diabetes and unstable or brittle diabetes. As sulfonylurea hypoglycaemic agents are not effective in juvenile onset, unstable or brittle diabetes, gliclazide should not be used in these conditions.

Hypersensitivity.

Gliclazide should not be used with patients with known sensitivity to sulfonylureas.

Impaired renal function.

Gliclazide is contraindicated in severe renal insufficiency. Caution should be exercised and dosage reduction may be required when using gliclazide in patients with impaired renal function.

Impaired hepatic function.

Gliclazide is contraindicated in severe hepatic insufficiency. Caution should be exercised and dosage reduction may be required when using gliclazide in patients with impaired hepatic function.
Treatment with miconazole (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
Pregnancy and lactation (see Section 4.6 Fertility, Pregnancy and Lactation).

4.4 Special Warnings and Precautions for Use

Acute complications such as severe trauma, fever, infection or surgery.

These acute complications provoke additional metabolic stress which accentuate the predisposition to hyperglycaemia and ketosis. Patients presenting with such conditions may require insulin to maintain control. It is not appropriate to increase the dosage of gliclazide.

Hypoglycaemia.

Close observation and careful initiation and adjustment of dosage is mandatory in patients who are elderly and debilitated, malnourished, semi starved or simply neglecting dietary restrictions. In such patients severe hypoglycaemia may occur with all sulfonylureas and may require corrective therapy over a period of several days. Certain conditions such as alcoholism, insulinoma, adrenal thyroid and pituitary insufficiency increase the sensitivity to sulfonylureas and may dispose to hypoglycaemia.
Careful selection of patients and of the dose used, as well as provision of adequate information to the patient are necessary to avoid hypoglycaemic episodes.
The following factors may increase the risk of hypoglycaemia:
patient does not follow the doctor's treatment advice (particularly elderly patients);
malnutrition;
irregular mealtimes, skipping meals, periods of fasting or dietary changes;
imbalance between physical exercise and carbohydrate intake;
renal impairment;
severe hepatic impairment;
overdose of anti-diabetic agents;
certain endocrine disorders: thyroid disorders, hypopituitarism and adrenal impairment, concomitant administration of certain other medicines (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
Gliclazide should only be prescribed if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycaemia if a meal is delayed, an inadequate amount of food is consumed or the food is low in carbohydrate. Hypoglycaemia is more likely to occur during periods of low-calorie diet, following prolonged or strenuous exercise, following alcohol intake or during treatment with a combination of hypoglycaemic agents.

Poor blood glucose control.

Blood glucose control in treated patients may be affected by St. John's Wort (Hypericum perforatum) preparations (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions), fever, trauma, infection or surgical intervention. It may be necessary to discontinue treatment and to administer insulin in these cases.
The efficacy of oral antidiabetic agents often decreases in the long term. This may be due to progression in the severity of the diabetes, or to a reduced response to treatment. This phenomenon is known as secondary failure and should be distinguished from primary failure, when the drug is ineffective as first-line treatment. However, before classifying the patient as a secondary failure, dose adjustment and reinforcement of dietary measures should be considered.

Unstable blood glucose level (dysglycaemia).

Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Indeed, careful monitoring of blood glucose is recommended in all patients receiving gliclazide and a fluoroquinolone at the same time.

Renal and hepatic impairment.

Severe renal or hepatic impairment may affect the distribution of gliclazide and hepatic impairment may also reduce the capacity for neoglucogenesis. These two effects increase the risk of severe hypoglycaemic reactions. A hypoglycaemic episode in these patients may be prolonged and appropriate management should be initiated.

Glucose-6-phosphate dehydrogenase deficiency (G6PD).

Treatment of patients with G6PD-deficiency with sulphonylurea agents can lead to haemolytic anaemia. Since gliclazide belongs to the chemical class of sulphonylurea drugs, caution should be used in patients with G6PD-deficiency and a non-sulphonylurea alternative should be considered.

Lactose intolerance.

Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose galactose malabsorption, or the Lapp lactase deficiency should not take this medicinal product.

Monitoring of diabetic state.

As with other antidiabetic therapies, patients must be under close medical supervision. Particular care must be taken during the initial period of stabilisation. Patients treated with gliclazide should be monitored regularly to ensure optimal control of the diabetic state, and where necessary, for adjustment of dosage.

Transferring to gliclazide.

Patients who have been previously treated with sulfonylureas or biguanides alone or in combination may be transferred to gliclazide. When gliclazide is administered as sole therapy to patients who have previously required combination therapy (e.g. biguanides and sulfonylureas), careful observation is essential during the transitional phase.
It is not generally recommended that insulin treated patients be transferred to gliclazide.

Patient awareness.

Comprehensive instructions must be given to the patient about the nature of the disease and what must be done to detect and prevent complications.

Patients with porphyria.

Cases of acute porphyria have been described with this class of sulfonylurea drugs, in patients who have porphyria.

Use in the elderly.

No information available.

Paediatric use.

Not recommended for paediatric use, see Section 4.2 Dose and Method of Administration.

Effects on laboratory tests.

Glycated haemoglobin should be monitored regularly. Blood glucose measurement may also be useful.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Disturbances of blood sugar control. As with all hypoglycaemics, caution should be observed in administering thiazide diuretics to patients on gliclazide therapy, since thiazides have been reported to aggravate the diabetic state. Other drugs which may adversely affect blood sugar control with hypoglycaemic agents in some patients include barbiturates, glucocorticoids and estrogens.
Potentiation of the blood glucose lowering effect and therefore in some instances, hypoglycaemia may occur when one of the following medications is taken:
Blood glucose monitoring during and after treatment is necessary when gliclazide is used with medicines which can interact with gliclazide. It may also be necessary to adjust the dose of gliclazide during and after treatment with such medicines.

1) The following medications are likely to increase the risk of hypoglycaemia.

Concomitant use which is contraindicated.

Miconazole (systemic route, oromucosal gel).

Increases the hypoglycaemic effect with possible onset of hypoglycaemia symptoms, or even coma.
Concomitant use which is not recommended.

Phenylbutazone (systemic route).

Increases the hypoglycaemic effect of sulphonylureas (displaces their binding to plasma proteins and/or reduces their elimination).
It is preferable to use a different anti-inflammatory agent, or else to warn the patient and emphasise the importance of self-monitoring. Where necessary, adjust the dose during and after treatment with the anti-inflammatory agent.

Alcohol.

Acute alcohol intoxication potentiates the hypoglycaemic action of all sulfonylurea by inhibiting compensatory reactions. This can lead to the onset of hypoglycaemic coma. Furthermore, ingestion of alcohol may cause a disulfiram like reaction with characteristic flushing of the face, throbbing headache, giddiness, tachypnoea, tachycardia or angina pectoris.
Chronic alcohol abuse may, as a result of liver enzyme induction, stimulate the metabolism of sulfonylurea drugs and shorten plasma half-life and duration of action.
Avoid alcohol or medicines containing alcohol.
Concomitant use which requires special care. Potentiation of the blood glucose lowering effect and therefore in some instances, hypoglycaemia may occur when one of the following medications is taken: other antidiabetic agents (insulin, acarbose, biguanides, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), sulfonamides, clarithromycin, oxyphenbutazone, phenylbutazone, clofibrate, salicylates (high doses), coumarin derivatives, chloramphenicol, monoamine oxidase inhibitors (MAOIs), beta-blockers, H2-receptor antagonists, ACE inhibitors, cimetidine, fluconazole and nonsteroidal anti-inflammatory agents and ethanol.

2) The following medications may cause an increase in blood glucose levels.

Advise the patient and emphasise the importance of glucose monitoring.
Concomitant use which is not recommended.

Danazol.

If the use of danazol cannot be avoided, it may be necessary to adjust the dose of gliclazide during and after treatment with danazol.
Concomitant use which requires special care.

Chlorpromazine.

High doses (> 100 mg per day of chlorpromazine) can increase blood glucose levels (reduced insulin release). Advise the patient and emphasise the importance of glucose monitoring. It may be necessary to adjust the dose of gliclazide during and after treatment with chlorpromazine.

Glucocorticoids (systemic and local route: intra-articular, cutaneous and rectal preparations) and tetracosactrin.

Concomitant use may increase blood glucose levels with possible ketosis (glucocorticoids cause reduced tolerance to carbohydrates). Emphasise the importance of blood glucose monitoring, particularly at the start of treatment. It may be necessary to adjust the dose of gliclazide during and after treatment with glucocorticoids.

Salbutamol, terbutaline (intravenous).

May cause increased blood glucose levels due to beta-2 agonist effects. If necessary, switch to insulin.

Barbiturates, estrogens and progestogens.

May adversely affect blood sugar control with hypoglycaemic agents in some patients by causing increased blood glucose levels.

St. John's Wort (Hypericum perforatum) preparations.

Gliclazide exposure is decreased by St John's Wort (Hypericum perforatum).

3) The following products may cause unstable blood glucose.

Concomitant use which requires special care.

Fluoroquinolones.

In case of a concomitant use of gliclazide and a fluoroquinolone, the patient should be warned of the risk of unstable blood glucose, and the importance of blood glucose monitoring should be emphasised.
Concomitant use to be taken into consideration.

Anticoagulant therapy (warfarin).

Sulphonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of warfarin may be necessary.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category C)
In animal studies embryo-toxicity and/or birth defects have been demonstrated with some sulfonylureas.
It is important to achieve strict normoglycaemia during pregnancy. Oral hypoglycaemic agents should be replaced by insulin.
The sulfonylureas may enter the fetal circulation and cause neonatal hypoglycaemia.
Gliclazide should not be used in pregnant women. Gliclazide is contraindicated during pregnancy and insulin is the drug of first choice for treatment of diabetes during pregnancy. Treatment should be changed from gliclazide to insulin therapy before pregnancy is attempted, or as soon as pregnancy is discovered. Control of diabetes should be achieved before the time of conception to reduce the risk of congenital abnormalities linked to uncontrolled diabetes.
It is not known whether gliclazide or its metabolites are excreted in breast milk. Given the risk of neonatal hypoglycaemia, gliclazide is contraindicated in women who are breast feeding. A risk to newborns/infants cannot be excluded.
Gliclazide should not be used during lactation.

4.7 Effects on Ability to Drive and Use Machines

Patients should be made aware of the symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.

4.8 Adverse Effects (Undesirable Effects)

Adverse reactions have occurred in some 12% of cases in clinical studies. However, approximately 2% of patients were withdrawn from therapy because of adverse reactions, notably hypoglycaemia, gastrointestinal disturbances (constipation, nausea, epigastric discomfort and heartburn), dermatological reactions (rash and transient itching), and biochemical abnormalities (elevated serum creatinine, increased serum alkaline phosphatase, raised serum AST, elevated BUN and raised serum bilirubin). Headache, slight disulfiram like reactions and lassitude have also been reported.
Serious reactions which have been reported with other sulfonylureas are leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, cholestatic jaundice and gastrointestinal haemorrhage. These reactions have not been reported with gliclazide.

Hypoglycaemia.

(See Section 4.4 Special Warnings and Precautions for Use; Section 4.9 Overdose).
The most frequent adverse reaction with gliclazide is hypoglycaemia.
As is the case with all sulphonylurea drugs, hypoglycaemic reactions have been reported following gliclazide administration. However, a number of studies have shown that hypoglycaemia is less common with gliclazide than with glibenclamide.
Possible symptoms of hypoglycaemia are: headache, intense hunger, nausea, vomiting, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and/or death. In addition, signs of adrenergic counter-regulation may be observed: sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.
Usually, symptoms disappear after intake of carbohydrate such as sugar (artificial sweeteners have no effect). Experience with other sulphonylureas shows that hypoglycaemia can recur even when these measures are initially effective. If a hypoglycaemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation is required.
As is the case with all forms of antidiabetic therapy, hypoglycaemic reactions have occasionally been reported following gliclazide administration.
Severe hypoglycaemia, though very rarely reported, may occur in patients receiving gliclazide.

Other adverse effects reported with gliclazide.

Gastrointestinal disturbances (reported with gliclazide), including nausea, dyspepsia, diarrhoea, abdominal pain, vomiting and constipation may be avoided or minimised if gliclazide is taken with breakfast.
The following adverse effects have been rarely reported:

Skin and subcutaneous tissue disorders.

Pruritus, urticaria, maculopapular rashes, rash, angioedema, erythema and bullous reactions (such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) (as with other sulfur-containing medications) and autoimmune bullous disorders and exceptionally, drug rash with eosinophilia and systemic symptoms (DRESS).

Blood and lymphatic system disorders (as with other sulphonylurea medications).

Anaemia, leucopenia, thrombocytopenia and agranulocytosis. These are in general reversible upon discontinuation of medication.

Hepatobiliary disorders.

Elevations of serum bilirubin and hepatic enzymes (AST, ALT, alkaline phosphatase) levels, and exceptionally, hepatitis (isolated reports). Treatment should be discontinued if cholestatic jaundice appears. These symptoms usually disappear after discontinuation of treatment.

Investigations.

Occasional elevations of serum creatinine, blood urea nitrogen.

Eye disorders.

Transient visual disturbances may occur due to changes in blood glucose levels, particularly on initiation of treatment. As with any glucose-lowering medication, transient visual disturbances may occur on initiation of treatment due to changes in blood glucose levels.

Class effects.

The following adverse events have been observed with sulphonylureas: cases of erythrocytopenia, agranulocytosis, haemolytic anaemia, pancytopenia and allergic vasculitis, hyponatremia, elevated liver enzyme levels and even impairment of liver function (e.g. with cholestasis and jaundice) and hepatitis which regressed after withdrawal of the sulphonylurea or led to life-threatening liver failure in isolated cases.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdose of sulphonylureas may cause hypoglycaemia.
Moderate symptoms of hypoglycaemia (without loss of consciousness or neurological signs), should be corrected by carbohydrate intake, dose adjustment and/or modification of diet. Strict monitoring should be continued until the doctor is sure that the patient is out of danger.
Severe hypoglycaemic reactions are possible (with coma, convulsions or other neurological disorders) and must be treated as a medical emergency, requiring immediate hospitalisation.
If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid I.V. injection of 50 mL of concentrated glucose solution (20 to 30%). This should be followed by continuous infusion of a more dilute glucose solution (10%) at a rate necessary to maintain blood glucose levels above 5 mmol/L. It is recommended that patients should be monitored closely for a 48 hour period at least.
Plasma clearance of gliclazide may be prolonged in patients with hepatic disease. However, due to the strong binding of gliclazide to proteins, dialysis is not effective in these patients.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Mode of action.

Gliclazide stimulates insulin secretion from functional pancreatic beta-cells and increases the sensitivity of the beta-cells to a glucose stimulus (some residual beta-cell function is therefore necessary). Gliclazide restores the diminished first phase of insulin secretion noted in non-insulin dependent diabetes mellitus.
Any long-term hypoglycaemic activity of gliclazide can be attributed to an ability to maintain its effect on insulin secretion. Extrapancreatic effects may also be involved in the long-term efficacy of gliclazide. Extrapancreatic effects demonstrated for gliclazide include improvement in insulin mediated glucose utilisation and potentiation of postreceptor insulin sensitive pathways.
At normal therapeutic doses in humans, gliclazide reduces platelet adhesiveness and aggregation.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Gliclazide is absorbed in the gastrointestinal tract reaching peak serum concentrations within four to six hours.
Single dose studies have demonstrated that maximal falls in blood glucose levels (23% of an 80 mg dose; 30% of a 160 mg dose) occur approximately five hours after drug administration; nine hours after a dose of 160 mg, a reduction of 20% was still in evidence.
The half-life of gliclazide is approximately twelve hours.

Distribution.

Gliclazide is distributed to the extracellular fluid. In animals, high concentrations of the drug were found in the liver, kidneys, skin, lungs, skeletal muscle, intestinal and cardiac tissue. Penetration of gliclazide into the central nervous system was negligible. Gliclazide crosses the placental barrier and penetrates the fetus. The apparent volume of distribution of gliclazide (20 to 40% expressed as a percentage bodyweight) is low and probably reflects the high degree of protein binding (94.2% at a plasma concentration of approximately 8 microgram/mL).

Metabolism.

Little information is available in the metabolism of gliclazide. At least eight metabolites (three major) have been observed by thin layer and gas-liquid chromatography. Some of these are glucuronic acid conjugates; only one of the metabolites has been identified (para-toluene sulfonamide). The liver is the probable site of metabolism.

Excretion.

Approximately 70% of the administered dose appears to be excreted in the urine and 11% in the faeces. The urinary excretion of the drug is slow and the maximum rates do not occur until seven to ten hours after initial administration. The metabolic products are detectable in the urine 120 hours after oral administration. Faecal elimination is usually complete within 144 hours of oral administration.

5.3 Preclinical Safety Data

Genotoxicity.

In animal studies embryotoxicity and/or birth defects have been demonstrated.

Carcinogenicity.

No animal studies have been performed that investigate the carcinogenic potential of gliclazide.

6 Pharmaceutical Particulars

6.1 List of Excipients

The tablets also contain the following excipients: lactose monohydrate, microcrystalline cellulose, povidone, purified talc, sodium starch glycollate type A and magnesium stearate. The tablets are gluten free.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C.

6.5 Nature and Contents of Container

Blister (AL/PVC/PVDC) packs 100's.
Bottle (HDPE/PE)* packs 100's.
*Bottle packs are not currently marketed in Australia.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Gliclazide is a white or almost white powder, practically insoluble in water, freely soluble in dichloromethane, sparingly soluble in acetone and slightly soluble in ethanol 96%.

Chemical structure.

Gliclazide. The chemical name for gliclazide is 1-(3-azabicyclo[3.3.0] oct- 3-yl)-3-para- tolylsulfonylurea. Its structural formula is:
C15H21N3O3S. Molecular weight: 323.4.

CAS number.

21187-98-4.

7 Medicine Schedule (Poisons Standard)

Prescription medicine (S4).

Summary Table of Changes